Video
Providing a New Approach to Patient Care: A Conversation with Pieter Mutendam from scPharmaceuticals
Author(s):
At the Heart Failure Society of America's 20th Annual Scientific Meeting, Pieter Muntendam, MD, scPharmaceuticals, discussed his work in developing a hospital strength treatment option for patients with fluid overload using the well known drug furosemide, now for subcutaneous administration.
At the Heart Failure Society of America's 20th Annual Scientific Meeting, Pieter Muntendam, MD, scPharmaceuticals, discussed his work in developing a hospital strength treatment option for patients with fluid overload using the well known drug furosemide, now for subcutaneous administration. Essentially after working in the field of heart failure for several years, Muntendam had recognized the need to improve diuretic options. He also noted that the sole purpose of them being in the hospital was to get the diuretic to help them lose the water and salt they had accumulated in the first place,which leads to unnecessary expenses. As such, he wanted to provide an option for patients to do the same thing at home at a fraction of the cost.
